Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REC-1245 · 1 trial · 4 indications
To characterize the incidence of DLTs
To characterize the incidence of treatment emergent adverse events
To assess tumor response
| Arm | Type | Description |
|---|---|---|
| Phase 1a | EXPERIMENTAL | Dose Finding |
| Phase 1b Cohort A | EXPERIMENTAL | - |
| Phase 1b Cohort B | EXPERIMENTAL | - |
| Phase 1b Cohort C | EXPERIMENTAL | - |
| Phase 1b Cohort D | EXPERIMENTAL | - |
| Phase 2 Cohort 1 Dose #1 | EXPERIMENTAL | - |
| Phase 2 Cohort 1 Dose #2 | EXPERIMENTAL | - |
| Phase 2 Cohort 2 Dose #1 | EXPERIMENTAL | - |
| Phase 2 Cohort 2 Dose #2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REC-1245 | DRUG | Oral |
Inclusion Criteria: * Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma * Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatme...
REC-1245 is an investigational small molecule being developed for the treatment of unresectable, locally advanced, or metastatic cancers, as well as relapsed or refractory lymphomas. It is currently being studied in a Phase 1 clinical trial.
REC-1245 targets RBM39, a protein involved in RNA splicing and gene regulation. By targeting RBM39, the drug aims to disrupt cancer cell survival mechanisms. This mechanism is being evaluated in the context of advanced solid tumors and lymphomas.
REC-1245 is being developed by Recursion Pharmaceuticals, Inc., a biopharmaceutical company listed on the Nasdaq under the ticker symbol RXRX. The company is conducting clinical trials for this investigational oncology drug.
REC-1245 is in Phase 1 of clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants to evaluate its safety and preliminary efficacy.
REC-1245 is being studied in a Phase 1 clinical trial with the identifier NCT06678659. This trial is enrolling approximately 170 participants with unresectable, locally advanced, or metastatic cancers, as well as relapsed or refractory lymphomas, at sites in the United States and Canada.
No, REC-1245 is not the same as RBM39. REC-1245 is the investigational drug name, while RBM39 is the molecular target of the drug. The drug is designed to interact with RBM39, but they are distinct entities.